GHK-Cu Research Overview — Copper Peptide Biology, Skin, and Wound Healing

Origin — Pickart, 1973

GHK (glycyl-L-histidyl-L-lysine) was first isolated from human plasma by Loren Pickart in 1973, published in Nature New Biology, as a growth-modulating factor found in albumin fractions. The tripeptide binds divalent copper with high affinity, forming a square-planar complex (GHK-Cu²⁺) that is the biologically active species in most of the published research.

Pickart has remained the central figure in GHK-Cu research for more than fifty years. His group has published on fibroblast activation, collagen and elastin gene expression, antioxidant effects, wound-healing models, and — more recently — gene-expression profiling showing that GHK-Cu modulates a wide array of transcripts in cultured human cells.

Mechanism — what copper peptides do in culture

The published mechanism of action for GHK-Cu involves several threads:

Fibroblast activation

Multiple in vitro studies report that GHK-Cu promotes proliferation and activation of dermal fibroblasts, the cells responsible for extracellular matrix production in connective tissue. Downstream effects include increased synthesis of type I collagen, glycosaminoglycans, and dermatan sulfate — the structural components of healthy dermis.

Gene-expression modulation

Pickart and colleagues (BioMed Research International 2015) reported transcriptome-level effects of GHK on cultured human cells, with modulation of DNA-repair, anti-inflammatory, and tissue-remodelling genes. The picture is less "GHK-Cu turns on one receptor" and more "GHK-Cu modulates a large suite of genes associated with tissue maintenance."

Antioxidant / redox effects

The copper-binding geometry of GHK-Cu allows it to chelate labile copper — which is pro-oxidant when free — and deliver it in a controlled form. This is part of the argument for a net antioxidant effect in tissue models, though the redox chemistry is nuanced and depends on local conditions.

Wound-healing literature

The wound-healing literature on GHK-Cu spans rodent models, rabbit ear models, and various ex-vivo skin systems. Reported effects include faster re-epithelialisation, increased granulation tissue formation, and stronger tensile strength in healed wounds compared with vehicle controls. As with any preclinical dermatology literature, effect sizes vary by model, concentration, and delivery vehicle.

There are scattered human case reports and small observational studies, mostly in the cosmetic-dermatology literature. There is no pivotal randomised controlled trial that would support a drug approval for GHK-Cu in any jurisdiction.

Cosmetic vs research-chemical framing

This is the distinction that matters most in Canada:

• Cosmetic GHK-Cu — low-concentration topical formulations sold as finished cosmetic products, regulated under the Canadian Cosmetic Regulations and requiring ingredient disclosure and safety notification. These are legitimate consumer products.
• Research-grade GHK-Cu — lyophilised synthetic peptide sold for non-clinical laboratory use. Not a finished product, not labelled for human use, and not within the cosmetic regulatory framework.

The two things look superficially similar but occupy different regulatory slots. A Canadian researcher ordering GHK-Cu from a peptide supplier is buying the research-chemical form — the raw peptide for in vitro or preclinical work.

Structural and handling notes

• Sequence: Gly-His-Lys (tripeptide).
• Copper coordination: 1:1 GHK:Cu²⁺, square-planar.
• Solubility: Water-soluble; typically reconstituted in bacteriostatic water for research work.
• Stability: Lyophilised material is stable at -20°C; reconstituted material refrigerated and used within 2–4 weeks. The copper complex is sensitive to extreme pH and to reducing agents that could shift copper oxidation state.

See the GHK-Cu encyclopedia entry for the full chemistry and current Canadian stock status.

How to read the literature

Three cues when reading GHK-Cu papers:

1. Is the species stated as GHK or GHK-Cu²⁺? The activity profile is different between the free tripeptide and the copper complex.
2. What is the concentration? Cosmetic-relevant concentrations are typically in the nM to low μM range; some wound-healing studies use higher concentrations.
3. What is the model? In vitro fibroblast effects are well documented; in vivo wound-healing effects are more variable; human clinical evidence is case-report level for non-cosmetic endpoints.

Summary

GHK-Cu has one of the oldest and most consistent preclinical stories in the research-peptide category, dating back to Pickart's 1973 Nature New Biology paper. The in vitro fibroblast and collagen data are robust; the wound-healing literature is extensive; the human clinical drug evidence is minimal. In Canada, cosmetic copper peptides are regulated as cosmetics, while research-grade GHK-Cu is sold strictly as a non-clinical research chemical.